Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

genzyme europe b.v., netherlands - agalsidase beta - powder for concentrate for solution for infusion - 5 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - agalsidase beta, quantity: 5.5 mg - injection, powder for - excipient ingredients: nitrogen; monobasic sodium phosphate monohydrate; mannitol; dibasic sodium phosphate heptahydrate - fabrazyme is indicated for the long-term enzyme replacement therapy in patients with a confirmed diagnosis of fabry disease (alpha-galactosidase deficiency).

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - agalsidase beta, quantity: 35 mg - injection, powder for - excipient ingredients: monobasic sodium phosphate; nitrogen; dibasic sodium phosphate heptahydrate; mannitol - fabrazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of fabry disease (alpha-galactosidase deficiency).